Interaction pharmacokinetics of pegylated liposomal doxorubicin (Caelyx) on coadministration with paclitaxel or docetaxel

@article{Briasoulis2003InteractionPO,
  title={Interaction pharmacokinetics of pegylated liposomal doxorubicin (Caelyx) on coadministration with paclitaxel or docetaxel},
  author={Evangelos Briasoulis and Vasilis Karavasilis and Eleftheria Tzamakou and D Rammou and Kali Soulti and Christina Piperidou and Nicholas Pavlidis},
  journal={Cancer Chemotherapy and Pharmacology},
  year={2003},
  volume={53},
  pages={452-457}
}
  • Evangelos Briasoulis, Vasilis Karavasilis, +4 authors Nicholas Pavlidis
  • Published 2003
  • Medicine
  • Cancer Chemotherapy and Pharmacology
  • PurposeTo investigate the pharmacokinetics of polyethylene glycol-coated liposomal doxorubicin (PLD, Caelyx) when given as a single agent and in combination with the taxanes paclitaxel or docetaxel in humans.MethodsThe plasma kinetics of PLD were studied in 19 cancer patients treated with PLD every 4 weeks combined with either paclitaxel (on a weekly basis in seven and as a single infusion in three patients) or docetaxel (weekly in seven and as a single infusion in two). Plasma concentrations… CONTINUE READING

    Citations

    Publications citing this paper.
    SHOWING 1-10 OF 37 CITATIONS, ESTIMATED 52% COVERAGE

    Factors affecting the pharmacokinetics of pegylated liposomal doxorubicin in patients

    VIEW 2 EXCERPTS
    CITES BACKGROUND

    Pegylated Liposomal Doxorubicin

    VIEW 1 EXCERPT
    CITES BACKGROUND

    What is the right way to administer pegylated liposomal doxorubicin in breast cancer therapy?

    Pharmacological basis of pegylated liposomal doxorubicin: impact on cancer therapy.

    FILTER CITATIONS BY YEAR

    2004
    2019

    CITATION STATISTICS

    • 2 Highly Influenced Citations

    References

    Publications referenced by this paper.
    SHOWING 1-10 OF 34 REFERENCES

    Human pharmacokinetic characterization and in vitro study of the interaction between doxorubicin and paclitaxel in patients with breast cancer.

    VIEW 2 EXCERPTS

    Phase I trial of pegylated liposomal doxorubicin and docetaxel in advanced breast cancer.

    VIEW 1 EXCERPT